Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.
Brief Summary: The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Control
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: solifenacin | Arm Label: Solifenacin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: solifenacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Solifenacin 5 mg | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 5 mg
C: Arm Label: Solifenacin; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin | Arm Label: Oxybutynin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin; Assigned to Arm(s): Solifenacin | Intervention Type: DRUG; Name: Oxybutynin; Assigned to Arm(s): Oxybutynin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1: Solifenacin 5 mg + Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 2: Solifenacin 5 mg + Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 4: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 5:Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 6: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 4: Solifenacin 5 mg | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match solifenacin succinate; Assigned to Arm(s): 3: Placebo, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 3: Placebo, 4: Solifenacin 5 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg

Answer: B